SIGY: Sigyn Therapeutics, Inc. Stock

by  •  • Comments Off on SIGY: Sigyn Therapeutics, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 8.43
Enterprise Value ($M) 10.48
Book Value ($M) -4.46
Book Value / Share -2.78
Price / Book -1.89
NCAV ($M) -4.65
NCAV / Share -2.90
Price / NCAV -1.81

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -10.33
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.00
Current Ratio 0.00

Balance Sheet (mrq) ($M)
Current Assets 0.02
Assets 0.21
Liabilities 4.67
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -2.52
Net Income -3.34
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.87
Cash from Investing 0.00
Cash from Financing 0.87

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Brio Capital Master Fund Ltd. 9.99 30.16

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)

Similar Companies
RYLPF – Koninklijke Philips N.V. SAUHF – Straumann Holding AG
SCIE – SpectraScience, Inc. SNNUF – Smith & Nephew plc
SONVF – Sonova Holding AG


Financial data and stock pages provided by
Fintel.io